Commentary on: The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience.
作者信息
Rutsch Frank, Salusky Isidro B, Ferreira Carlos R
机构信息
Department of General Pediatrics and Center for Rare Diseases, Muenster University Children's Hospital, Muenster, Germany.
Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
出版信息
J Nephrol. 2024 Nov;37(8):2059-2060. doi: 10.1007/s40620-024-02057-9. Epub 2024 Aug 20.
Abstract
摘要
相似文献
1
Commentary on: The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience.关于《布罗索尤单抗治疗2型常染色体隐性低磷性佝偻病：理论依据及首次临床经验》的述评
J Nephrol. 2024 Nov;37(8):2059-2060. doi: 10.1007/s40620-024-02057-9. Epub 2024 Aug 20.
2
The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience.布罗索尤单抗治疗2型常染色体隐性低磷性佝偻病：理论依据及首次临床经验
J Nephrol. 2024 Jun;37(5):1371-1374. doi: 10.1007/s40620-023-01884-6. Epub 2024 Feb 3.
3
Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).布罗索尤单抗治疗常染色体隐性遗传性低磷血症性佝偻病 1 型（ARHR1）。
J Clin Endocrinol Metab. 2022 Sep 28;107(10):2777-2783. doi: 10.1210/clinem/dgac433.
4
Lessons learned from the real-world diagnosis and management of hereditary hypophosphatemic rickets.从遗传性低磷性佝偻病的真实世界诊断与管理中吸取的经验教训。
Bone Rep. 2024 Mar 21;21:101753. doi: 10.1016/j.bonr.2024.101753. eCollection 2024 Jun.
5
Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.真实世界中布罗索尤单抗治疗 X 连锁低磷血症性佝偻病患儿的疗效。
Pediatr Nephrol. 2022 Nov;37(11):2667-2677. doi: 10.1007/s00467-022-05484-7. Epub 2022 Feb 24.
6
Burosumab: A new drug to treat hypophosphatemic rickets.布罗索尤单抗：一种治疗低磷性佝偻病的新药。
Sudan J Paediatr. 2017;17(2):71-73. doi: 10.24911/SJP.2017.2.11.
7
Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.布罗索尤单抗改善 X 连锁低磷血症性佝偻病青少年磷代谢、骨骼健康和生活质量的安全性和有效性。
Eur J Med Genet. 2024 Aug;70:104958. doi: 10.1016/j.ejmg.2024.104958. Epub 2024 Jun 29.
8
Recurrent Soft Tissue Infections Associated With Burosumab Therapy in X-Linked Hypophosphatemic Rickets.与布罗索尤单抗治疗X连锁低磷血症性佝偻病相关的复发性软组织感染
JCEM Case Rep. 2023 Nov 7;1(6):luad120. doi: 10.1210/jcemcr/luad120. eCollection 2023 Nov.
9
Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) due to ENPP1-deficiency.常染色体隐性低血磷性佝偻病 2 型（ARHR2），系由于 ENPP1 缺乏所致。
Bone. 2021 Dec;153:116111. doi: 10.1016/j.bone.2021.116111. Epub 2021 Jul 9.
10
A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome.病例报告：首例皮肤-骨骼低磷血症综合征患者接受布罗索尤单抗长期治疗。
Front Endocrinol (Lausanne). 2022 May 6;13:866831. doi: 10.3389/fendo.2022.866831. eCollection 2022.
本文引用的文献
1
The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience.布罗索尤单抗治疗2型常染色体隐性低磷性佝偻病：理论依据及首次临床经验
J Nephrol. 2024 Jun;37(5):1371-1374. doi: 10.1007/s40620-023-01884-6. Epub 2024 Feb 3.
2
Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies.异位钙化和低磷性佝偻病：ENPP1 和 ABCC6 缺乏症的自然病史。
J Bone Miner Res. 2021 Nov;36(11):2193-2202. doi: 10.1002/jbmr.4418. Epub 2021 Aug 16.
3
Correspondence on "Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al.费雷拉等人关于“婴儿期全身性动脉钙化（GACI）长期幸存者的前瞻性表型分析”的通信
Genet Med. 2021 Oct;23(10):2006-2007. doi: 10.1038/s41436-021-01228-4. Epub 2021 Jun 14.
4
ENPP1-Fc prevents neointima formation in generalized arterial calcification of infancy through the generation of AMP.ENPP1-Fc 通过生成 AMP 来防止婴儿全身性动脉钙化中的新生内膜形成。
Exp Mol Med. 2018 Oct 29;50(10):1-12. doi: 10.1038/s12276-018-0163-5.
5
PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification.特发性婴儿动脉钙化中的PC-1核苷三磷酸焦磷酸水解酶缺乏症。
Am J Pathol. 2001 Feb;158(2):543-54. doi: 10.1016/S0002-9440(10)63996-X.
Zotero 插件